| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Aug 2025 | 7 Aug 2025 |
| Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June 2025 | ||
| Board Meeting | 12 Jul 2025 | 12 Jul 2025 |
| Board meeting to approve issue period and letter of offer Submission of Corrigendum of Outcome of Board meeting held on July 12, 2025 | ||
| Board Meeting | 9 Jul 2025 | 9 Jul 2025 |
| Issue of equity shares of company on right issue basis Board of Directors meeting held today, i.e., July 9, 2025, has, inter alia, considered and approved the following terms of the Rights Issue: Total number of securities proposed to be 13,98,463 fully paid-up Equity Shares of issued 2 (Two) Rights Equity Shares of 210/ - each for every 23 (Twenty-Three) Equity Shares of %10/ - each held by the Eligible Equity Shareholders in the Company as on the record date, with the right to renounce. Issue Price Rs. 357/- per Rights Equity Share (including premium of 347/- per Rights Equity Share and Face Value of 10/ - each). Outstanding Equity Shares prior to the 1,60,82,319 Equity Shares of 10/- each Rights Issue Outstanding Equity Shares post Rights 1,74,80,782 Equity Shares of %10/- each Issue (assuming full subscription) (assuming full subscription). | ||
| Board Meeting | 2 Jul 2025 | 29 Jun 2025 |
| Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2025 inter alia to consider and approve for fund raising by way of issue of equity shares through right issue through right issue Raising of Fund by way of issue of equity shares of the company on right issue basis (As Per BSE Announcement Dated on :02.07.2025) | ||
| Board Meeting | 19 May 2025 | 13 May 2025 |
| Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter ended 31st March 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 19/05/2025) | ||
| Board Meeting | 11 Feb 2025 | 3 Feb 2025 |
| KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve unaudited standalone and consolidated financial results for the quarter ended 31st December 2024 Considered and Approved unaudited financial results for quarter ending 31st December, 2024 (As per BSE Announcement Dated on 11/02/2025) | ||
| Board Meeting | 12 Nov 2024 | 4 Nov 2024 |
| KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th September 2024. We are submitting herewith the financial results for the quarter ended 30th September, 2024 (As Per BSE Announcement Dated on: 12/11/2024) | ||
| Board Meeting | 30 Aug 2024 | 30 Aug 2024 |
| Pursuant to Regulation 30 of SEBI LODR Regulations, this is to inform you that the Board of Directors approved the appointment of M/s C Sharat & Company, Chartered Accountants as a Statutory Auditors of the Company | ||
| Board Meeting | 26 Aug 2024 | 26 Aug 2024 |
| Appointment of M/s. AVHP & Company LLP, Chartered Accountant (FRN:W100671) as Statutory Auditors of the Company | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.